NCT05883748Phase 2, phase 3Enrolling by invitation

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

Study sponsor: Disc Medicine, Inc · IRON

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06Estimated
Enrollment · participants230Estimated
Source updated2026-10-09Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Planned enrollment increased by 30 participants

Before: 200 participants (planned). After: 230 participants (planned).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview